The Union Government will open at least 3,000 Jan Aushadhi stores by FY2017 to supply quality generic medicines across India, with 300 stores to open by FY2016. Boehringer Ingelheim and Lupin entered an agreement for Lupin to co-promote Boehringer's diabetes drug Linagliptin in India. Suven Life Sciences secured several patents for its neuro-degenerative drug across major markets such as China, South Korea, Europe, Australia and the US.

1. Policy News
 By FY2017, 3,000 Jan Aushadhi stores to open
The Union Government will open at least 3,000 Jan Aushadhi stores by FY2017, of which 300 stores will
be launched in the country by FY2016. This initiative is a part of Jan Aushadhi Scheme to supply quality
and affordable generic medicines across India, mainly for the poor. The government has signed a
memorandum of understanding (MoU) with a retail chain, CISSIL, to open 100 stores across Kerala by
November 2015. As per the deal, CISSIL will provide the generic medicines from the stores in their super
markets. Bureau of Pharma’s public sector undertakings would provide one-time assistance of INR 2.50
lakhs to set up a Jan Aushadhi outlet. Moreover in the next two months, around 184 Jan Aushadhi stores
which are already operational in the country will supply at least 425 generic medicines.
Industry News
 Boehringer Ingelheim, Lupin to co-market Linagliptin in India
Boehringer Ingelheim and Lupin have entered into a strategic agreement to co-market anti-diabetes drug
Linagliptin - a novel Dipeptidylpeptidase-4 (DPP-4) inhibitor - in India. As per the contract, Lupin’s
diabetes specialty field force will promote the drugs, marketed under new brand names - Ondero Met
(fixed-dose combination with metformin) and Ondero (monotherapy). This initiative will not only expand
the company’s diabetes portfolio, but also help it to consolidate its position as the fastest growing player
in the top-5 anti-diabetes segment. Boehringer will carry out the sale of Linagliptin under the brand
names Trajenta Duo (fixed-dose combination with metformin) and Trajenta (monotherapy) through its
existing network and sales force. In India, the DPP-4 Inhibitors market is worth INR 1,499 crore and is
growing at 26.55 percent. The anti-diabetic portfolio accounts for 15 percent of Lupin's India
formulations sales.
 Suven Life secures patent for neuro-degenerative drug
Pharma company, Suven Life Sciences has secured patents from China, South Korea, Europe, Australia
and the US for its neuro-degenerative drug. The patents from China and South Korea are valid until 2030,
while patents from the rest of the regions are valid until 2031. Currently, the company has 22 granted
patents from Australia, 17 from Europe, 19 from China, 23 from the US and 17 from South Korea. Suven
has achieved these patents through its internal discovery research efforts. It patents in these markets are
for new chemical entities for CNS therapy through mechanism of action - H3 Inverse. At various phases of
clinical development, products developed from these inventions are likely to be out-licensed.
 Roche Pharma rolls out new breast cancer drug
Switzerland-based pharma company, Roche India has launched two new medicines - Perjeta and Kadcyla
- to treat breast cancer. These drugs will increase survival and improve the quality of life for metastatic
HER2-positive breast cancer patients. However, the pricing details of the two drugs were not
declared. Roche’s breast cancer medicine, Herclon, has been available in India for several years.
© Gyan Research and Analytics Pvt. Ltd., 2015 1
Healthcare News
October 10, 2015 – October 16, 2015

2. © Gyan Research and Analytics Pvt. Ltd., 2015 2
 PMDA plans to open India office
Pharmaceuticals and Medical Devices Agency (PMDA), the drug regulator of Japan, plans to open an
office in India to help Indian generic drug manufacturers who wanted to increase their presence in Japan
either through export or partnering with Japanese companies. PMDA aims to lower healthcare costs by
encouraging generic drugs, as the regulator is concerned about the ageing population and increasing
healthcare costs in Japan, which are dominated by branded drugs. Currently, Japan’s healthcare market is
about USD 110 billion. Japan aims to double the share of generics in its healthcare system by FY2018, in
order to simplify the burden on public expenditure and transforming it into an attractive opportunity for
Indian firms.
 Aurobindo Pharma receives approval from USFDA for Alzheimer drug
Aurobindo Pharma received the final approval for the Abbreviated New Drug Application (ANDA) from
the US Food and Drug Administration (USFDA) to manufacture and sell Memantine Hydrochloride tablets
of capacity 5 mg and 10 mg. These tablets are used in treatment of Alzheimer's disease. It is an extension
of March 24, 2015 tentative approval. The approved tablet has a projected market size of USD 1.23
billion for the next 12 months which ends on August 2016. Aurobindo Pharma has a total of 215 ANDA
approvals (188 final approvals including 10 from Aurolife Pharma LLC and 27 tentative approvals) from
USFDA.
 ICMR calls for tribal health research
The Director General of Indian Council of Medical Research (ICMR) has pointed out the need for new
research on tribal health in a collaborative effort by ICMR, government agencies and voluntary
organizations. With fast changing living standards, tribals have become more vulnerable to non-
communicable diseases. A central government research wing will undertake a research programme to
outline programmes and policies for tribal health.
 Reliance Life Sciences, Epirus terminates deal for Remicade
Reliance Life Sciences has ended its deal with Boston-based Epirus Biopharmaceuticals to supply
Remicade biosimilars. This drug is used to treat various diseases such as ulcerative colitis and rheumatoid
arthritis. The move came as part of an internationally mediated dispute settlement between the
two. Earlier, Epirus had tied up with Reliance for local supplies of the drug, manufactured by the latter at
its site near Mumbai. However, thereafter Epirus entered into two separate contracts with Livzon
MabPharm and Fujifilm Diosynth Biotechnologies for supplies of the same drug. Reliance alleged that
Epirus had violated its exclusive global supply rights for the biosimilar drug - coded as BOW015.
Healthcare News
October 10, 2015 – October 16, 2015

3. © Gyan Research and Analytics Pvt. Ltd., 2015 3
Investment news
 Apollo Hospitals to raise funds for expansion
Apollo Hospitals Enterprise plans to raise up to INR 750 crore through a rights issue to fund the expansion
of its healthcare business. Apollo will establish new hospitals in Bengaluru, Mumbai, Guwahati and
Visakhapatnam. The company will investment INR 550 crore in Mumbai, INR 150 crore in Visakhapatnam
and INR 170 crore in Bengaluru. The company's board had approved the rights issue in May and is
awaiting regulatory approvals. Going forward, Apollo Health & Lifestyle Limited (AHLL) will also raise up
to INR 500 crore through private equity partners for expansion. In India, AHLL operates a network of
primary care as well as special care formats.
 Mankind Pharma invested INR 150 crore in its Paonta Sahib plant
Mankind Pharma has invested INR 150 crore in its Paonta Sahib plant and aims to launch 35 products by
the end of 2016. The company is concentrating on nutraceuticals manufacturing at a growth rate of 35
percent. It is also focusing on the production of food supplements and beverages. Currently, the
company's 80 percent of the niche molecules have been concentrated in the production of nutraceuticals
and it has recently introduced 24 products under the segment.
Healthcare News
October 10, 2015 – October 16, 2015
Weekly Snapshot
Market growth in the Indian Pharma Industry as on September 10, 2015
Type of market Market growth
Gynecological 13.4
Respiratory 4.1
Pain and Analgesics 9
Anti-infectives 3.2
Gastronial 12.8
Anti-diabetic 18.1
Cardiac 11.8
Dermatologist 12.9
Urology 12.1
Source: AIOCD PharmaSoftech AWACS

4. © Gyan Research and Analytics Pvt. Ltd., 2015 4
Market Entry
Strategies
Market/
Marketing
Research
Pre-Feasibility,
Feasibility & TEV
Studies
Equity
Research
& Valuation
Economic
Intelligence
Our Business Practices
Business
Research
Central Delivery
Centre
BD-9, Sector-1,
Salt Lake City
Kolkata - 700 064,
India
Phone: +91-33-
40060084
Corporate Office
LG 37-38, Ansal
Fortune Arcade,
Sector - 18,
Noida - 201 301
Delhi NCR, India
Phone: +91-120-
2511945
E-mail: reports@gyananalytics.com
Website: www.gyananalytics.com
Branch Office -
Mumbai
Branch Office
- Bangalore
Branch Office
- Hyderabad
Healthcare News, October 10, 2015 – October 16, 2015